GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Operating Margin %

NaviFUS (ROCO:6872) Operating Margin % : -2,263.95% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. NaviFUS's Operating Income for the six months ended in Dec. 2023 was NT$-50.49 Mil. NaviFUS's Revenue for the six months ended in Dec. 2023 was NT$2.23 Mil. Therefore, NaviFUS's Operating Margin % for the quarter that ended in Dec. 2023 was -2,263.95%.

The historical rank and industry rank for NaviFUS's Operating Margin % or its related term are showing as below:

ROCO:6872' s Operating Margin % Range Over the Past 10 Years
Min: -373.34   Med: -356.65   Max: -339.96
Current: -339.96


ROCO:6872's Operating Margin % is ranked worse than
59.79% of 1027 companies
in the Biotechnology industry
Industry Median: -161.26 vs ROCO:6872: -339.96

NaviFUS's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

NaviFUS's Operating Income for the six months ended in Dec. 2023 was NT$-50.49 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-76.43 Mil.


NaviFUS Operating Margin % Historical Data

The historical data trend for NaviFUS's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Operating Margin % Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - - -373.34 -339.96

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - -242.62 -626.92 -128.09 -2,263.95

Competitive Comparison of NaviFUS's Operating Margin %

For the Biotechnology subindustry, NaviFUS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NaviFUS's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NaviFUS's Operating Margin % distribution charts can be found below:

* The bar in red indicates where NaviFUS's Operating Margin % falls into.



NaviFUS Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

NaviFUS's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-76.426 / 22.481
=-339.96 %

NaviFUS's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-50.486 / 2.23
=-2,263.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NaviFUS  (ROCO:6872) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


NaviFUS Operating Margin % Related Terms

Thank you for viewing the detailed overview of NaviFUS's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS (ROCO:6872) Business Description

Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines